← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
76	76 Immix Biopharma IMMX $706M	109	+32	+42%	$580M
77	77 Korro Bio KRRO $131M	106	+7	+7%	$190M
78	78 Invesco Biotechnology & Genome ETF PBE $421M	104	+4	+4%	$94.1M
79	79 Opus Genetics IRD $341M	103	+24	+30%	$236M
80	80 Tenaya Therapeutics TNYA $87.6M	101	-2	-2%	$39.7M
81	81 Century Therapeutics IPSC $250M	100	+28	+39%	$387M
82	82 Precision BioSciences DTIL $166M	95	+17	+22%	$139M
83	83 Cartesian Therapeutics RNAC $192M	94	+11	+13%	$90.4M
84	84 Lyell Immunopharma LYEL $196M	87	+13	+18%	$178M
85	85 Benitec Biopharma BNTC $289M	86	-2	-2%	$443M
86	86 Autolus Therapeutics AUTL $450M	83	-1	-1%	$212M
87	87 Immatics IMTX $1.07B	82	-2	-2%	$1.01B
88	88 INmune Bio INMB $44.4M	82	0	0%	$7.08M
89	89 Fractyl Health GUTS $54.1M	77	-6	-7%	$56.2M
90	90 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	76	-14	-16%	$960M
91	91 Artiva Biotherapeutics ARTV $289M	72	+32	+80%	$392M
92	92 Mesoblast MESO $1.79B	72	+3	+4%	$53.3M
93	93 Silence Therapeutics SLN $558M	72	+16	+29%	$239M
94	94 PepGen PEPG $161M	71	-22	-24%	$93.7M
95	95 ProKidney PROK $307M	71	0	0%	$99.5M
96	96 SOPHiA GENETICS SOPH $601M	71	+22	+45%	$213M
97	97 ProQR Therapeutics PRQR $207M	70	+1	+1%	$113M
98	98 iShares Genomics Immunology and Healthcare ETF IDNA $312M	65	+5	+8%	$85.8M
99	99 Cibus CBUS $107M	62	-4	-6%	$25.9M
100	100 CAMP4 Therapeutics CAMP $215M	61	+15	+33%	$182M